3 source-based articles maintained by the HealthRX.com Editorial Team.
Showing 3 of 3 clinical reviews.
A detailed methodological breakdown of the SURPASS-3 trial comparing tirzepatide to insulin degludec in type 2 diabetes, covering randomization, blinding, estimand framework, comparator choice, and how each design decision shapes clinical interpretation.
Deep-dive into the SURPASS-3 open-label extension: durability of tirzepatide's A1C and weight benefits vs insulin degludec over 52 additional weeks, safety signals, and long-term clinical implications.
A plain-English deep dive into the SURPASS-3 trial comparing tirzepatide vs insulin degludec in type 2 diabetes, covering methodology, results, limitations, and clinical implications.